(Press-News.org) New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to a higher rate of heart-related conditions compared to medications that hit other targets. The study examined nationwide data from nearly 50,000 patients treated with different sulfonylureas and found that glipizide – the most widely used drug in the U.S. within this category – was linked to higher incidence of heart failure, related hospitalization and death compared to dipeptidyl peptidase-4 (DPP-4) inhibitors. Results are published in JAMA Network Open.
“Patients with type 2 diabetes are at heightened risk of adverse cardiovascular incidents such as stroke and cardiac arrest,” said corresponding author Alexander Turchin, MD, MS, of the Division of Endocrinology at Brigham and Women’s Hospital (BWH), a founding member of the Mass General Brigham healthcare system. “While sulfonylureas are popular and affordable diabetes medications, there is a lack of long-term clinical data on how they affect cardiac health in comparison to more neutral alternatives like dipeptidyl peptidase 4 inhibitors.”
Turchin and co-authors emulated a target trial by analyzing electronic health records and insurance claims data from the BESTMED consortium. The cohort included 48,165 patients with type 2 diabetes and moderate cardiovascular risk who received care at 10 different study sites across the country, including BWH, as well as those covered by two different national health insurance plans.
The researchers studied the five-year risk of major adverse cardiovascular events in patients treated with different sulfonylureas (glimepiride, glipizide or glyburide) or DPP4i in addition to metformin, a primary diabetes medication. They found that glipizide was associated with a 13% increase in cardiovascular risk when compared to DPP4i, while glimepiride and glyburide led to relatively smaller and less clear effects, respectively. The authors propose that further research is needed to uncover the underlying mechanisms.
“Our study underscores the importance of evaluating each drug in a particular pharmacological class on its own merits,” said Turchin.
Authorship: In addition to Turchin, Mass General Brigham authors include Marie E. McDonnell. Additional authors include Miguel A. Hernán, Lucia C. Petito, Emma Hegermiller, Ryan Carnahan, Andrea DeVries, Satyender Goel, M. Cecilia Lansang, Vinit Nair, Elisa Priest, Vincent J. Willey, and Alan F. Kaul.
Disclosures: Turchin reported receiving grants from Eli Lilly and personal fees from Novo Nordisk and Proteomics International. Petito reported receiving grants from Omron Healthcare Co, Ltd. Lansang reported receiving grants from Abbott and Dexcom. Priest reported receiving grants from Boehringer Ingelheim, AstraZeneca, CSL Vifor, and Owkin. Willey reported being employed by Carelon Research. Hernán reported receiving personal fees from Cytel and ProPublica, being a consultant to Adigens Health (a company of which he owns equity), and being a member of the ADIALab Advisory Board; his interests were declared, reviewed, and approved by Harvard University in accordance with its institutional compliance policies. No other disclosures were reported.
Funding: This study was funded in part by the Patient-Centered Outcomes Research Institute (contract Nos. DB-2020C2-20308 and RI-MISSOURI-01-PS1).
Paper cited: Turchin, A. et al. “Cardiovascular Events in Individuals Treated With Sulfonylureas or Dipeptidyl Peptidase 4 Inhibitors.” JAMA Network Open. DOI: 10.1001/jamanetworkopen.2025.23067
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
END
Cancer cells and tumors do not exist in a vacuum. Far from the isolation and self-sufficiency of the fictional Wakanda, tumors develop in and alter the nearby milieu of immune cells, connective tissue, blood vessels and a sea of proteins and carbohydrates that provide structure and other supportive functions.
Cancer cells interact with this neighborhood — which scientists term the tumor microenvironment — in many ways, including obtaining extra resources needed to fuel their unchecked growth. Like a fishing trawler deploying its net, pancreatic ductal adenocarcinoma (PDAC) ...
About The Study: Among men with traditional Medicare, this study examined racial differences in 2 important measures of prostate cancer care quality that have contrasting relationships with utilization. Black men had lower odds of confirmatory testing among those on active surveillance, where utilization and quality are tightly aligned, indicating worse care. Conversely, Black men had lower odds of overtreatment, where utilization and quality are misaligned, suggesting better care in this dimension.
Corresponding Author: To contact the corresponding author, Arnav Srivastava, MD, MPH, MS, email srivasar@med.umich.edu.
To access ...
About The Study: In this economic evaluation, undergoing risk-reducing mastectomy (RRM) appears cost-effective for women ages 30 to 55 with a lifetime breast cancer risk of 35% or higher. These results could have significant clinical implications to expand access to RRM beyond BRCA1/BRCA2/PALB2 pathogenic variant carriers. Future studies evaluating the acceptability, uptake, and long-term outcomes of RRM among these women are warranted.
Corresponding Author: To contact the corresponding author, Ranjit Manchanda, MD, PhD, email r.manchanda@qmul.ac.uk.
To access the embargoed study: Visit our For The ...
As artificial intelligence is rapidly developing and becoming a growing presence in healthcare communication, a new study addresses a concern that large language models (LLMs) can reinforce harmful stereotypes by using stigmatizing language. The study from researchers at Mass General Brigham found that more than 35% of responses in answers related to alcohol- and substance use-related conditions contained stigmatizing language. But the researchers also highlight that targeted prompts can be used to substantially reduce stigmatizing language in the LLMs’ answers. Results are published in The Journal of Addiction Medicine.
“Using patient-centered language can build ...
A study just published on Eurosurveillance has found evidence of substantial lifetime exposure to hepatitis B and C viruses in Ukraine in a 2021 nationwide, representative sample of the population, with findings also suggesting significant ongoing circulation of these viruses.
Ahead of World Hepatitis Day 2025, viral hepatitis remains a major global health concern, and is one of the priority infectious diseases under the United Nations’ Sustainable Development Goal 3. [1][2] The World Health Organization (WHO) Global Hepatitis ...
The National Biofoundry Project Team at the Korea Research Institute of Bioscience and Biotechnology (KRIBB), led by Dr. Haseong Kim, has spearheaded an international joint research effort (including institutions from Korea, the U.S., the U.K., Singapore, and others—10 in total) to create a new standard framework that simplifies and enhances the accuracy and efficiency of synthetic biology research. This framework is anticipated to serve as an international standard for biofoundries—automated laboratories in synthetic biology.
Driven by advancements in deep-tech fields such as synthetic biology ...
Use of billing codes in big data sets to find diagnoses can result in up to two-thirds of cases being mistakenly identified, new UCLA-led research finds.
Databases frequently used for medical research such as those for the Centers for Medicare & Medicaid Services or the National Inpatient Survey typically rely on ambulatory billing codes to identify diseases or medical procedures, but their accuracy is rarely verified in publications that rely on this data, the researchers write in a report published in the peer-reviewed journal ...
Hospitalizations and emergency department (ED) visits can be distressing and costly for nursing home residents – especially those who are severely impaired or terminally ill. Despite their vulnerability, these individuals are frequently transferred to hospitals, even though up to 40% of such transfers over the past 25 years are considered potentially avoidable by health care professionals.
These unnecessary transfers not only cause distress and discomfort for residents and families but also lead to hospital-acquired complications and added costs for the health care system. In the United States, hospital transfers from nursing homes significantly ...
Schizophrenia is a serious mental health condition that affects thoughts, moods, perceptions, and behaviors. Affected individuals experience positive symptoms like delusions and hallucinations, and negative symptoms like social withdrawal, cognitive deficits, disorganized thoughts and speech, and a decreased experience of pleasure. While schizophrenia is caused by a complex interplay of genetic, environmental, and lifestyle factors, precise mechanisms remain elusive.
Animal models provide valuable insights into the neurobiological mechanisms that underpin schizophrenia. However, conventional behavioral assessments ...
Chemotherapy-induced nausea and vomiting are among the most distressing side effects of anti-cancer treatment, particularly for those receiving highly emetogenic regimens such as anthracycline plus cyclophosphamide combinations. This major side effect compromises a patient’s quality of life and willingness to continue therapy. Therefore, there is a crucial need to devise an effective antiemetic management approach for optimizing cancer care and patient well-being.
Against this backdrop, a new study, led by Professor Mitsue ...
